A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
Gilles A. Salles
Research Funding - Gilead Sciences
Nicole Lamanna
Research Funding - Gilead Sciences
Bipinkumar R. Amin
Research Funding - Gilead Sciences
Ralph V. Boccia
Research Funding - Gilead Sciences
Nashat Y. Gabrail
Research Funding - Gilead Sciences
Muhammad-Ali A. Zaydan
Research Funding - Gilead Sciences
Michelle Wong
Employment or Leadership Position - Gilead Sciences
Adeboye H. Adewoye
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences